The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Cancer-Associated Venous Thromboembolism

Increased thrombotic risk in cancer patients requiring tailored prevention and treatment.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Cancer-Associated Venous Thromboembolism?

Cancer increases the risk of venous thromboembolism (VTE) by 4-7 fold compared with the general population. VTE is the second leading cause of death in cancer patients after cancer itself. The pathogenesis involves tumor procoagulant factors (tissue factor, podoplanin), platelet activation, endothelial injury, immobility, and treatment effects (chemotherapy, antiangiogenics, hormonal therapy, surgery, central catheters).

VTE risk varies markedly by cancer type, with highest rates in pancreatic, gastric, brain, ovarian, and hematologic malignancies. The Khorana score and other validated tools stratify ambulatory chemotherapy patients for thromboprophylaxis. Hospitalized cancer patients have substantially elevated risk and warrant pharmacologic prophylaxis unless contraindicated.

Treatment has evolved from low-molecular-weight heparin (LMWH) monotherapy to direct oral anticoagulants (DOACs: apixaban, rivaroxaban, edoxaban) for many patients, with caution in luminal GI cancers due to bleeding risk. Extended anticoagulation beyond 6 months is recommended in active cancer. Recurrent VTE on adequate anticoagulation requires LMWH dose escalation.

Symptoms

Unilateral leg swelling, warmth, redness (DVT)
Calf tenderness or pain
Sudden dyspnea, pleuritic chest pain (PE)
Tachycardia, hypotension in massive PE
Hemoptysis
Syncope
Hypoxemia on pulse oximetry
Upper extremity swelling (catheter-associated thrombosis)
Cerebral venous thrombosis: headache, focal deficits, seizures
Splanchnic vein thrombosis: abdominal pain, ascites
Marantic endocarditis with embolic events
Asymptomatic incidental PE on staging CT

Risk Factors

Active cancer, particularly pancreatic, gastric, brain, ovarian, lung
Metastatic disease
Recent surgery (particularly abdominopelvic, neurosurgery)
Hospitalization with reduced mobility
Chemotherapy (cisplatin, anti-angiogenic, immunomodulatory)
Hormonal therapy (tamoxifen, exogenous estrogen)
Central venous catheter or port
Prior VTE history
Inherited thrombophilia
Obesity
Older age
Erythropoiesis-stimulating agents
Khorana score 2 or higher in ambulatory chemotherapy

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • New unilateral leg swelling or pain
  • Sudden shortness of breath, chest pain
  • Fast heart rate, lightheadedness
  • Coughing up blood
  • Persistent headache with focal symptoms
  • Severe abdominal pain with ascites
  • Catheter-related arm swelling
  • Recurrent VTE despite anticoagulation
  • Bleeding on anticoagulation

Treatment Methods

01
Risk assessment with Khorana score in ambulatory chemotherapy
02
Outpatient thromboprophylaxis: apixaban or rivaroxaban for high-risk Khorana 2+
03
Hospital prophylaxis: LMWH, fondaparinux, or DOAC unless contraindicated
04
Extended postoperative prophylaxis 4 weeks for major abdominopelvic cancer surgery
05
Acute VTE treatment options: LMWH (dalteparin, enoxaparin, tinzaparin), DOAC (apixaban 10 mg BID x 7 days then 5 mg BID, rivaroxaban 15 mg BID x 21 days then 20 mg daily, edoxaban after 5 days LMWH)
06
Caution with DOAC in luminal GI or genitourinary cancer (LMWH preferred)
07
Avoid DOAC in moderate-severe liver disease or renal failure
08
Anticoagulation duration: at least 6 months, extended while cancer active
09
IVC filter only when anticoagulation absolutely contraindicated
10
Recurrent VTE on therapeutic anticoagulation: switch DOAC to LMWH or escalate LMWH dose 25%
11
Catheter-associated thrombosis: anticoagulation 3 months, retain functional catheter
12
Cerebral venous thrombosis: anticoagulation despite intracranial bleed risk
13
Splanchnic vein thrombosis: individualized anticoagulation balancing bleed risk
14
Bleeding management: hold anticoagulation, reverse with idarucizumab (dabigatran) or andexanet (factor Xa inhibitors)
15
Patient education on signs of recurrence and bleeding
16
Avoid concurrent antiplatelets unless cardiovascular indication
17
Coordinate with oncology to optimize cancer treatment around anticoagulation
18
Consider switching to LMWH around chemotherapy if thrombocytopenia
19
Monitor renal and liver function periodically
20
Discuss risk-benefit at each oncology visit

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.